The objective of this study was to evaluate the effects of angiotensin-converting enzyme (ACE) inhibitors and pharmacogenetic interaction on the survival of the patients with diastolic heart failure (DHF). A total of 285 subjects with DHF confirmed by echocardiography were recruited in the period between 1995 and 2003. Baseline characteristics (age, sex, prior history, medication, and echocardiographic findings) and genetic polymorphisms (ACE gene insertion/ deletion (I/D) polymorphism; T174M, M235T, G-6A, A-20C, G-152A, and G-217A polymorphisms of the angiotensinogen (AGT) gene; and A1166C polymorphisms of the angiotensin II type I receptor (AT1R)) were collected and matched (by propensity score) in those who received and those who did not receive ACE inhibitors. The patients were followed up to 10 years. Kaplan-Meier curves and Cox regression models were used to demonstrate the survival trend. The 85 patients who received ACE inhibitors and the other 85 patients who did not were found to have comparable baseline characteristics and polymorphism distribution. Prescription of ACE inhibitors was associated with a significant decrease in overall mortality (hazard ratio (HR), 0.45; 95% confidence interval (CI), 0.24-0.83; P ¼ 0.01), and a lower rate of cardiovascular events at 4000 days (HR, 0.53; 95% CI, 0.32-0.90; P ¼ 0.02). In addition, ACE I/D gene D allele was associated with higher overall mortality as compared with the I allele (HR, 2.04; P ¼ 0.003). This effect was diminished in those who received ACE inhibitors. The use of ACE inhibitor was associated with a significant decrease in long-term mortality and cardiovascular events in the patients with DHF. Genetic variants in the renin-angiotensin system genes were also associated, but their effects could be modified by the use of ACE inhibitors.
Introduction
Heart failure (HF) is a commonly encountered hemodynamic and neurohormonal syndrome with increasing prevalence as the population ages and therapies for coronary artery disease improve. 1 Among the general HF population, over half have diastolic HF (DHF). [2] [3] [4] Observation studies have concluded that the morbidity associated with DHF (including the rate of hospitalization) is similar to that associated with systolic HF. 5 Large randomized trials in selected patients with HF have led to major advances in the medical treatment of systolic HF. [6] [7] [8] On the contrary, few randomized trials have been carried out with regard to medical management of DHF, despite its high prevalence and mortality. Therefore, treatment of DHF is still empirical and there is a scarcity of evidence-based recommendation towards the disease.
At present, there is little information about the prognostic influence of angiotensin-converting enzyme (ACE) inhibitors on DHF. A recent study performed in a European cohort concluded that prescription of ACE inhibitors was associated with a significant decrease in long-term mortality. 9 Nevertheless, a randomized multicenter study performed in China with DHF revealed that diuretics in combination with either ACE inhibitors or angiotensin II type I receptor (AT1R) blockers (ARB) did not have an additional effect in 1 year, with the left ventricular function improving only marginally. 10 In this prospective study, we followed a cohort of consecutive patients hospitalized for coronary angiography or for a health examination. We hypothesized that ACE inhibitors given to the patients with DHF might be associated with a decrease in long-term mortality. In addition, we genotyped eight polymorphisms among renin-angiotensin system (RAS) genes and aimed to examine the genetic effects and pharmacogenetic effects on survival in the patients with DHF.
Materials and methods

Study subjects
All the patients admitted to the cardiovascular ward of National Taiwan University Hospital for coronary angiography or a health examination from July 1995 to March 2003 were enrolled for echocardiographic examinations. DHF was defined as (1) exertional dyspnea (New York Heart Association function class II-III), (2) HF on the basis of Framingham criteria and normal systolic function (ejection fraction 50%), and (3) echocardiographic evidence of left ventricular diastolic dysfunction: a mitral inflow E/A ratio o1, deceleration time 4220 cm s -1 , and decreased peak annular early diastolic velocity of the lateral mitral annulus o8 cm s -1 in tissue Doppler imaging. 11 Patients who had renal failure, significant hepatic disease, secondary hypertension, pericardial disease, severe valvular heart disease, cancer, chronic obstructive pulmonary disease, or chronic atrial fibrillation were excluded. Patients who died or experienced cardiovascular events o60 days after enrollment were also excluded from the study. A total of 285 patients fulfilled the above criteria for DHF. Among them, the decision to prescribe ACE inhibitors or an ARB was based on the discretion and preference of the attending cardiologists.
Demographic data were collected from medical records. Hypertension was defined as systolic blood pressure of X140 mm Hg, diastolic blood pressure of X90 mm Hg, or the use of at least one class of antihypertensive agent. Type II diabetes mellitus was defined as a fasting blood glucose concentration 4126 mg per 100 ml and/or the use of at least one oral hypoglycemic agent. Medication information such as the use of ACE inhibitors and/or ARBs, calcium channel blockers, diuretics, nitrates, or b-blockers was recorded.
Identification of diallelic polymorphisms
Eight diallelic polymorphisms, including the ACE gene I/D polymorphism (rs1799752), G-217A (rs5049), G-152A (rs11568020), A-20C (rs5050), G-6A (rs5051), M235T (rs699; T4072C), and T174M (rs4762; C3889T) polymorphisms of the AGT gene, and the A1166C polymorphism (rs5186) of the AT1R gene within the RAS were analyzed in each of the 285 patients with DHF. Genomic deoxyribonucleic acid was extracted by using a nonenzymatic method. Deoxyribonucleic acid fragments were amplified by the polymerase chain reaction (PCR). ACE gene I/D polymorphisms were genotyped as reported earlier.
12,13 AT1R gene A1166C polymorphisms were genotyped by using the PCRrestriction fragment length polymorphism method. To genotype AGT gene polymorphisms, we used mini-PCR direct sequencing as described earlier. 13 
Ethics
The study was approved by local committee on medical research ethics. Written informed consent was obtained from all study participants.
PS-based matching
The PS is a method used to balance observed covariates in two treatment groups. [14] [15] [16] [17] In this study, the PS was the conditional probability for getting ACE inhibitors, as a binary-dependent variable, under a set of measurements. Clinical risk factors, such as sex, age, hypertension, diabetes, left ventricular mass, medication use, coronary artery disease, blood creatinine levels, the number of diseased coronary arteries, previous myocardial infarction, hemoglobin levels, dyslipidemia, severity of valvular heart disease, genetic polymorphisms, and medication history in addition to ACE inhibitors were added into a nonparsimonious multivariable logistic regression model to predict the predilection for the use of ACE inhibitors. The predicted probability derived from the logistic equation was used as the PS for each individual. Patients taking ACE inhibitors and those who did not were pooled together and sorted according to their PS in an ascending order. The patients who took and who did not take ACE inhibitors were matched by their PS in 1:1, 2:2, 3:3, or 4:4 blocks. Subjects that failed to find an appropriate match within the acceptable rank range were excluded from further analysis. The remaining patients constituted a well-matched 1:1 prospective cohort study.
End points
The primary outcome was defined as death from any cause. The secondary end points were (1) cardiovascular death, including mortality from stroke, myocardial infarction, arrhythmia, HF, and (2) cardiovascular events, including hospitalization due to myocardial infarction, recurrent coronary artery disease, stroke, peripheral artery occlusion disease, HF, and arrhythmia.
Follow-up
The follow-up period ended on 30 June 2007. All the patients visited our out-clinic at least every 3 months; otherwise, they would be interviewed by telephone annually. All the patients were carefully followed. The longest follow-up time was 4593 days. The information for primary or secondary outcomes was documented by chart record and by telephone interview.
Statistics
Baseline characteristics, genetic data, and echocardiographic findings between the two matched groups were compared by the Student's t test (continuous variables) and w 2 test (categorical variables). Hardy-Weinberg equilibrium of the polymorphism distribution was tested by w 2 . The survival time was defined as the duration from the day of enrollment to the occurrence of an event (primary or secondary end points). If an event did not occur, the case was regarded as censorship at the end of the study (30 July 2007) . Kaplan-Meier curves were plotted to show the survival trend; HR, 95% CI, and P-value were reported for the comparison between the two matched groups. A multiple Cox regression model in which the eight polymorphisms were added on top of ACE inhibitor status was applied to demonstrate the genetic effect on survival.
In addition, we split the DHF patients into ACE inhibitor users and No-ACE inhibitor users, and plotted Kaplan-Meier curves separately to illustrate the differential effect the diallelic polymorphisms had on survival, with and without the use of ACE inhibitors.
For all tests, a P-value p0.05 was considered statistically significant. Statistical analysis was performed under the SPSS (Statistical Package for the Social Sciences) 15.0 environment (SPSS Inc. Chicago, IL, USA). The study was approved by the Institutional Review Board, and informed consents were obtained from all the patients.
Results
Baseline characteristics
Initially, ACE inhibitors were prescribed to 106 of the 285 DHF patients (37%). Their baseline characteristics, echocardiographic data, and genetic polymorphisms are shown in Table 1 . Patients receiving ACE inhibitors were younger and more often had dyslipidemia and previous myocardial infarction. Other medication taken and the polymorphism distribution were factors that were not associated with whether ACE inhibitors were prescribed.
The propensity score (PS)-based selection process identified 85 patients receiving ACE inhibitors (the ACE inhibitor group) and the other 85 who did not receive ACE inhibitors (the No-ACE inhibitor group). There was no statistical difference in age, sex, co-morbidity, medication (except ACE inhibitors), other clinical variables, and even genotype distribution between the two groups ( Table 1 ). The median follow-up period was 8.7 years in the ACE inhibitor group (interquartile range, 5.8-10.8 years), and 6.4 years in the No-ACE inhibitor group (interquartile range, 4.8-9.1 years). No patient was lost to follow-up in either group.
Primary end point
The primary outcome (all-cause mortality) occurred in 15 (18%) patients in the ACE inhibitor group and 28 (33%) patients in the No-ACE inhibitor group. The 1000-, 2000-, and 4000-day cumulative all-cause mortality was 4, 14, and 18%, respectively, in the former group as compared with 9, 21, and 33% in the latter ( Table 2 ). The Kaplan-Meier curve showed that the hazard ratio (HR) was 0.45 (95% confidence interval (CI), 0.24-0.83; P ¼ 0.01) at 4000 days, favoring the use of ACE inhibitors (Figure 1 ).
Secondary end points
Cardiovascular death occurred in 3 (4%), 10 (12%), and 11 (13%) of cases in the ACE inhibitor group at 1000, 2000, and 4000 days as compared with 6 (7%), 13 (15%), and 16 (19%) in the No-ACE inhibitor group (Table 2) . At the end of 4000 days, there was no statistical difference in cardiovascular death between the two groups (HR, 0.60; 95% CI, 0.28-1.29;
Cardiovascular events occurred in 16 (19%), 20 (24%), and 23 (27%) in the ACE inhibitor group at 1000, 2000, and 4000 days, respectively, as compared with 23 (27%), 35 (41%), and 37 (44%) in the No-ACE inhibitor group (Table  2) . A Kaplan-Meier survival curve showed a significant reduction of cardiovascular events at the end of follow-up (HR, 0.53; 95% CI, 0.32-0.90; P ¼ 0.02) (Figure 3 ).
Genotypes and survival
The genotype distribution of the ACE gene insertion/ deletion (I/D) polymorphism, G-217A, G-152A, A-20C, G-6A, M235T, and T174M polymorphisms of the angiotensinogen (AGT) gene, and the A1166C polymorphism of the AT1R gene in the two groups are listed in Table 1 . The genotype proportions (Table 1) were in Hardy-Weinberg equilibrium, and polymorphisms were independently distributed.
In the multiple Cox regression model adjusted for the ACE inhibitor effect, the ACE I/D gene D allele induced a 2.04-fold hazard compared with the I allele (HR, 2.04; 95% CI, 1.27-3.27; P ¼ 0.003), and the AT1R A1166C C allele had a higher HR than the A allele (HR, 2.08; 95% CI, 1.27-3.45; P ¼ 0.004) ( Table 3) .
The ACE I/D gene was associated with survival in either dominant or recessive genetic models (HR, 2.95; 95% CI, 1.05-8.25; P ¼ 0.04 and HR, 2.48; 95% CI, 1.28-4.82; P ¼ 0.007), whereas the AT1R gene A1166C polymorphism was associated with survival in the dominant model (HR, 3.45; 95% CI, 1.56-7.69; P ¼ 0.002) ( Table 4) .
Pharmacogenetic effects
To evaluate the pharmacogenetic interaction, we further examined the effect of the ACE I/D gene and the AT1R gene A1166C on survival separately in patients who received ACE inhibitors and those who did not. In the No-ACE inhibitor group, the ACE I/D gene was associated with all-cause mortality in either the additive or dominant genetic models (HR, 2.23; 95% CI, 1.24-4.19; P ¼ 0.008 and HR, 2.67; 95% CI, 1.22-5.85; P ¼ 0.01). However, in the other group to whom ACE inhibitors was applied, the ACE I/D gene effect on survival was no longer significant with either the additive or the dominant genetic model (HR, 1.64; 95% CI, 0.77-3.15; P ¼ 0.20 and HR, 1.27; 95% CI, 0.43-3.78; P ¼ 0.67) ( Table 4 ). This result suggests that ACE inhibitors modulate the association between the ACE gene I/D polymorphism and the survival of DHF patients.
Nevertheless, the interaction effect was not observed on the AT1R gene. The AT1R gene A1166C C allele had a higher hazard than the A allele, both in the ACE inhibitor group 
Discussion
An estimated 450% of patients in the community with HF have preserved ejection fraction, and isolated diastolic dysfunction is present in 440% of cases. Although several studies showed a favorable effect of ACE inhibitors in the patients with DHF, solid evidence is lacking and controversies remain. [18] [19] [20] In this study, we used a homogenous Taiwanese population and matched a variety of confounding factors that might have influenced the prognosis of DHF. The results showed that overall mortality and cardiovascular events significantly diminished after the use of ACE inhibitors.
Medical therapy remains empirical in the patients with DHF because large randomized clinical trials are still lacking. The only two completed randomized trials regarding DHF with ACE inhibitors and ARBs are the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-preserved (CHARM-preserved) trial and the perindopril in elderly people with chronic heart failure (PEP-CHF) trial. 21 The CHARM-preserved trial failed to show a significant decrease in the risk of mortality, though hospitalization rates tended to decrease in 5 years or less of followup. 22 The PEP-CHF trial demonstrated that perindopril improved symptoms and functional capacities, but had no effect on the primary end point (all-cause mortality and HFrelated hospitalizations). In our study, the patients experienced the advantages of cardiovascular protection after 
Survival Free of Death from Cardiovascular Events
Hazard ratio, 0.60; 95% CI(0. 5 years and a reduction in overall mortality after 410 years. In comparison to previous studies, we performed a PS analysis to eliminate the confounding effects of baseline characteristics that might have influenced the survival of DHF. In addition, we carefully followed this cohort for a much longer period of time than previous trials so as to demonstrate the survival difference.
The patients in this study were older, male-dominant, and more prevalent in coronary artery disease; and therefore, activation of RAS might be more substantial. An ACE inhibitor might be the right choice to offer additional survival benefit. However, compared with a recent study performed in the European population in which ACE inhibitors improved mortality for around 5 years of follow-up, 9 our data suggest that the effects remain significant later in the treatment course, up to 10 years.
Genetic influence of RAS gene polymorphisms on cardiovascular disease, especially the susceptibility and progression of HF, has been widely studied. 23, 24 In the general population, the ACE I/D D allele has been related to cardiovascular mortality in several meta-analyses, although such association was not duplicated by others. [25] [26] [27] Our recent studies found that patients with the ACE I/D gene D allele and AT1R gene A1166C C allele in RAS genes were more likely to develop DHF. 28, 29 In this study, we demonstrated that the ACE I/D gene D allele and AT1R gene A1166C C allele were associated not only with the development of DHF but also with the long-term prognosis. Furthermore, the genetic association of the ACE I/D polymorphism with mortality was prominent in those who did not take ACE inhibitors, but was not significant in the patients who took ACE inhibitors. This pharmacogenetic interaction suggests that the adverse effect associated with genetic polymorphisms could be counteracted or even reversed by appropriate medical treatment.
Previous studies revealed that subjects with ACE DD genotypes were associated with a higher level of plasma
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Hazard ratio, 0.53; 95% CI(0.32-0.90); P=0.02 angiotensin II concentrations. 23 It has been shown that angiotensin II downregulates the expression of sarcoplasmic reticulum calcium ATP-ase in cardiomyocytes, which subsequently impairs left ventricular relaxation during the diastolic phase. 30 Prolonged left ventricular diastolic function may further lead to the development of left ventricular systolic function, lung congestion, and may also raise the morbidity and mortality rates. This study has proved that intervention with ACE inhibitors in patients with specific genotypes may block that vicious process and counteract the chances for mortality.
On the other hand, AT1R is the major receptor that mediates most of the physiologic action of angiotensin II, which is known to increase collagen synthesis in the myocardium. 24 Sanderson et al. 31 showed that a variant of the AT1R gene C allele was associated with an increased frequency of hospital admission in patients with congestive HF. Our results imply that increased myocardial collagen synthesis and stiffness associated with the AT1R C allele may lead to the development of DHF and result in more hospitalization and higher mortality, which may not be resolved by the use of ACE inhibitors.
In our study, the decision to prescribe ACE inhibitors was made by attending cardiologists, not by randomization. One limitation of the PS matching was that it only dealt with known variables. Some unknown factors unevenly distributing in the ACE inhibitor group and the No-ACE inhibitor group might still possibly affect the long-term outcome. In addition, the sample size was relatively small. A large-scale randomized trial with a time span of up to 10 years is still warranted. However, the propensity analysis eliminated some selection bias and confounding effects, and therefore improved the validity of the results. The case number, despite being small, is sufficient to provide enough power to demonstrate the benefit of ACE inhibitors in reducing overall mortality and cardiovascular events.
In conclusion, our study has demonstrated that the use of ACE inhibitors is associated with a significant decrease in overall mortality and cardiovascular events in patients with DHF. In addition, genetic variation or polymorphisms in the RAS is also associated with long-term survival; however, the effects can be modified by the use of ACE inhibitors.
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